NEW YORK (GenomeWeb News) – Leica Biosystems today announced it has acquired Kreatech Diagnostics for an undisclosed amount.
Kreatech, based in Amsterdam, is a provider of DNA fluorescent in situ hybridization probes and target labeling reagents for microarrays. It will join Leica's Advanced Staining Business Unit based in Newcastle-upon-Tyne UK.
In a statement, Matthias Weber, president of Leica, a Danaher company, said the deal allows Leica to better serve its cytogenetics and anatomic pathology customers and will "enable us to actively support the future development of personalized medicine by research and drug development companies."
Leica offers its ThermoBrite and Bond systems for labeling tissue specimens for diagnostic interpretation in cytogenetics and pathology laboratories.